Skip to main content

Gemfibrozil Pregnancy and Breastfeeding Warnings

Gemfibrozil is also known as: Lopid

Medically reviewed by Last updated on Feb 12, 2021.

Gemfibrozil Pregnancy Warnings

Use is recommended only if clearly needed and the benefit outweighs the risk

AU TGA pregnancy category: B3
US FDA pregnancy category: Not assigned

Risk Summary: This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; adverse effects have been observed in rats and rabbits at doses between 0.5 and 3 times the expected human dose.

Comments: The physiological hyperlipidemia of pregnancy does not require treatment.

Female rats receiving 2 times the estimated human dose (based on body surface area) from before and throughout gestation showed a dose-related decrease in conception rate, an increase in stillborns, a slight reduction in pup weight during lactation, dose-related increased skeletal variations, and rarely anophthalmia. Female rats dosed with 0.6 to 2 times the estimated human dose from gestation day 15 through weaning showed dose-related decreases in birth weight and suppressions of pup growth during lactation. Reversible decreases in male fertility have been observed in reproductive toxicity studies in rats. There are no controlled data in human pregnancy.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Gemfibrozil Breastfeeding Warnings

Use should be avoided.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-This drug should not be used while breastfeeding due to concern over disruption of infant lipid metabolism and the potential for tumorigenicity.

See references

References for pregnancy information

  1. "Product Information. Lopid (gemfibrozil)." Parke-Davis, Morris Plains, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Lopid (gemfibrozil)." Parke-Davis, Morris Plains, NJ.
  4. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.